Physician profile
Amer Issa
NPI 1326302712
$46,943.41
in general payments reported to CMS, 2019-2025
41 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $1,008 · 2021: $583 · 2022: $8,541 · 2023: $11K · 2024: $14K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $7,830 · Travel and Lodging: $1,117 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,453.64 |
| Food and Beverage | $7,830.07 |
| Travel and Lodging | $1,117.49 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38,198.52 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $970.27 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $968.00 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $746.06 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $648.28 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.26 | 2020-2025 | Jardiance |
| Amgen INC. | $508.12 | 2020-2025 | Tepezza, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $465.62 | 2019-2024 | Farxiga |
| Insulet Corporation | $434.19 | 2020-2025 | Omnipod |
| Abbott Laboratories | $411.30 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $380.96 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $322.00 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $317.18 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Abbvie INC. | $316.64 | 2023-2025 | |
| Radius Health, INC. | $217.62 | 2020-2025 | Tymlos |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $198.17 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $155.72 | 2022-2025 | |
| Medtronic Minimed, INC. | $146.88 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $111.59 | 2025 | Yorvipath |
| Beta Bionics, INC. | $109.89 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $93.15 | 2022-2025 | Tirosint, Licart, Flector |
| Recordati_rare_diseases_inc. | $82.05 | 2023-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $73.74 | 2023-2025 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $65.55 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $62.92 | 2024-2025 | |
| Tolmar, INC. | $44.69 | 2023-2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $37.97 | 2020 | |
| Alvogen INC | $36.89 | 2023-2025 | Teriparatide |
| Cequr Corporation | $28.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.06 | 2020 | |
| Averitas Pharma INC. | $24.73 | 2025 | Qutenza |
| Astellas Pharma US INC | $23.58 | 2024 | Veozah |
| Pfizer INC. | $23.02 | 2022 | |
| Ascensia Diabetes Care US INC. | $22.29 | 2025 | |
| Madrigal Pharmaceuticals | $17.61 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $17.50 | 2020 | |
| Horizon Therapeutics Plc | $15.89 | 2023 | Tepezza |
| Verity Pharmaceuticals INC. | $15.85 | 2025 | Tlando |
| Currax Pharmaceuticals LLC | $15.71 | 2025 | Contrave |
| Companion Medical, INC. | $15.14 | 2019 | |
| Halozyme INC | $14.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.